

# The evolving role of clinical pharmacists in chronic disease management: Evidence and implementation.

Lianne Torres\*

Department of Clinical Therapeutics, University of Paris Descartes, France

\*Correspondence to: Lianne Torres, Department of Clinical Therapeutics, University of Paris Descartes, France. E-mail: [l.torres@parispharma.fr](mailto:l.torres@parispharma.fr)

**Received:** 1-Jan-2025, Manuscript No. aajptr-25-168697; **Editor assigned:** 4-Jan-2025, PreQC No. aajptr-25-168697 (PQ); **Reviewed:** 18-Jan-2025, QC No. aajptr-25-168697; **Revised:** 25-Jan-2025, Manuscript No. aajptr-25-168697 (R); **Published:** 30-Jan-2025, DOI: 10.35841/aajptr-9.1.184

## Introduction

In recent decades, the role of clinical pharmacists has expanded significantly, transitioning from a traditional dispensing function to becoming integral members of the multidisciplinary healthcare team. This evolution is especially prominent in the context of chronic disease management, where clinical pharmacists play a crucial role in improving patient outcomes, optimizing medication use, and reducing healthcare costs. With the global rise in chronic conditions such as diabetes, hypertension, cardiovascular disease, asthma, and chronic obstructive pulmonary disease (COPD), the expertise of clinical pharmacists has become increasingly indispensable [1].

Clinical pharmacists are uniquely positioned to contribute to chronic disease care due to their extensive knowledge of pharmacotherapy, drug interactions, and patient education. By working collaboratively with physicians, nurses, and other healthcare professionals, they help tailor treatment regimens based on patient-specific factors, monitor therapy effectiveness, and adjust medications when needed. This team-based approach has been shown to enhance the quality of care and reduce medication-related complications [2].

Numerous studies have demonstrated that clinical pharmacist-led interventions can significantly improve health outcomes in chronic disease patients. For instance, pharmacists involved in diabetes management programs have helped patients achieve better glycemic control, evidenced by reductions in HbA1c levels. Similarly, in hypertension care, pharmacist-managed programs have been associated with improved blood pressure control, adherence, and reduced cardiovascular

risks. In asthma and COPD, pharmacists contribute by ensuring correct inhaler techniques, minimizing exacerbations, and encouraging smoking cessation [3].

One of the critical areas where clinical pharmacists add value is medication therapy management (MTM). MTM encompasses a range of services, including medication reconciliation, comprehensive medication reviews, and identifying and resolving drug-related problems. In chronic disease management, this ensures that patients are on the most effective and safe regimens, minimizes polypharmacy risks, and improves adherence. MTM has been linked with reduced hospital readmissions and emergency visits in multiple chronic disease populations [4].

Patient education and counseling are central to the pharmacist's role, particularly in promoting medication adherence—a frequent challenge in long-term treatment. By providing clear information about medications, side effects, and lifestyle modifications, pharmacists empower patients to take an active role in managing their conditions. This education also includes guidance on dietary choices, physical activity, and monitoring of disease-specific parameters such as glucose or blood pressure levels [5].

## Conclusion

In conclusion, the evolving role of clinical pharmacists represents a paradigm shift in chronic disease care. Their expertise in pharmacotherapy, coupled with a patient-centered approach, contributes significantly to the prevention, management, and monitoring of chronic illnesses. Moving forward, efforts must focus on removing barriers to implementation, enhancing

**Citation:** Torres L. The evolving role of clinical pharmacists in chronic disease management: Evidence and implementation. *J Pharmacol Ther Res.* 2025;9(1):184.

interprofessional collaboration, and fostering health policies that support the full utilization of clinical pharmacists in managing the global burden of chronic diseases.

## References

1. Soares M, Madeira S, Correia J, et al. Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization. *Breast*. 2016;27:44-51.
2. Spinelli JB, Yoon H, Ringel AE, et al. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. *Science*. 2017;358:941-946.
3. Tretter L, Patocs A, Chinopoulos C. Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. *BBA-Bioenergetics*. 2016;1857:1086-1101.
4. Smilowitz JT, O'Sullivan A, Barile D, et al. The human milk metabolome reveals diverse oligosaccharide profiles. *J Nutr*. 2013;143:1709-1718.
5. Zappulli V, Rasotto R, Caliarì D, et al. Prognostic evaluation of feline mammary carcinomas: A review of the literature. *Vet Pathol*. 2015;52:46-60.

**Citation:** Torres L. The evolving role of clinical pharmacists in chronic disease management: Evidence and implementation. *J Pharmacol Ther Res*. 2025;9(1):184.